Fig. 2From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysisOverall survival and progression-free survival a The median OS was better in the cetuximab group than the bevacizumab group; b the median PFS did not differ significantly between patients treated with cetuximab and bevacizumab)Back to article page